Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Feigelson, Heather Spencer ^a   Goddard, Katrina A B ^b   Johnson, Monique A ^c   Funk, Kellyan C ^a   Rahm, Alanna Kulchak ^a   Kauffman, Tia L ^b   Chitale, Dhananjay A ^d   Le Marchand, Loic ^e   Richards, C Sue ^c  

^a KAISER PERMANENTE   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Colorectal cancer; EGFR; KRAS; Laboratory error

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; PARAFFIN; RAS PROTEIN;

ADENOCARCINOMA; AGED; ARTICLE; CARCINOMA; CODON; COLORECTAL TUMOR; DIAGNOSTIC PROCEDURE; GENETICS; HUMAN; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; OBSERVER VARIATION; PATHOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; STANDARD; TISSUE FIXATION; UNITED STATES;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA; CLINICAL LABORATORY TECHNIQUES; CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; GUIDELINES AS TOPIC; HUMANS; MIDDLE AGED; MUTATION; OBSERVER VARIATION; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; QUALITY CONTROL; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION; UNITED STATES;

EID: 84862199032     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-196     Document Type: Article

References (13)

1. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA, Ann Intern Med 2011 154 37 49 21200037
2. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. J Clin Oncol 2009 27 2091 2096 10.1200/JCO.2009.21.9170 19188670
3. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. Franklin WA, Haney J, Sugita M, Bemis L, Jimeno A, Messersmith WA, J Mol Diagn 2010 12 43 50 10.2353/jmoldx.2010.080131 20007845
4. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. Holdhoff M, Schmidt K, Donehower R, Diaz LA, J Natl Cancer Inst 2009 101 1284 1285 10.1093/jnci/djp240 19641175
5. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG, J Clin Oncol 2009 27 1130 1136 10.1200/JCO.2008.19.8168 19124802
6. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. Br J Cancer 2009 101 715 721 10.1038/sj.bjc.6605177 19603018
7. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, et al. Cancer Res 2010 70 5901 5911 10.1158/0008-5472.CAN-10-0192 20570890
8. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Carotenuto P, Roma C, Rachiglio AM, Tatangelo F, Pinto C, Ciardiello F, et al. Pharmacogenomics 2010 11 1169 1179 10.2217/pgs.10.86 20712532
9. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, et al. J Mol Diagn 2009 11 543 552 10.2353/jmoldx.2009. 090057 19815694
10. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, et al. J Mol Diagn 2010 12 35 42 10.2353/jmoldx.2010.090079 20007841
11. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: Diagnostic and clinical implications. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, et al. J Mol Diagn 2010 12 1 8 10.2353/jmoldx.2010.090194
12. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A, Conde E, Hidalgo M, et al. J Mol Diagn 2010 12 292 299 10.2353/jmoldx.2010.090139 20203003
13. A comparability study of 5 commercial KRAS tests. Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ, et al. Diagn Pathol 2010 5 23 10.1186/1746-1596-5-23 20398393